Gilead prices Covid-19 drug remdesivir at $2,340 in developed nations

Gilead Sciences Inc on Monday priced its Covid-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.

The price tag is slightly below the range of $2,520 to $2,800 suggested last week by U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) after British researchers said they found that the cheap, widely available steroid dexamethasone significantly reduced mortality among severely ill Covid-19 patients.

Remdesivir is expected to be in high demand as one of the only treatments so far shown to alter the course of Covid-19. After the intravenously administered medicine helped shorten hospital recovery times in a clinical trial, it won emergency use authorization in the United States and full approval in Japan.